Retinal pharmacotherapeutics Developments in Ophtalmology Series, Vol. 55
Langue : Anglais
British Medical Association Medical book awards 2016: "Highly Commended" in the category Internal Medicine
The use of pharmacotherapeutics in the management of retinal diseases is
rapidly evolving, and a favorable therapy for the patient. Today anti-VEGF
agents are used for a range of indications from inflammation-related
choroidal neovascularization to macular edema secondary to retinal vein
occlusion or diabetic retinopathy. Beyond VEGF, there is an array of
target areas under investigation – not only for vascular pathologies such
as age-related macular degeneration and diabetic eye disease, but also for
degenerative, infectious and inflammatory retinal conditions.
This publication discusses many aspects from basic research on the retina,
to animal models for retinal drug delivery, retinal diseases that are
amenable to pharmacotherapy and also drugs and mechanisms in retinal
diseases. Anyone concerned with the management of retinal diseases - the
general ophthalmologist and the retina specialist alike – will find this
book indispensable reading.
Date de parution : 10-2015
Ouvrage de 408 p.
Disponible chez l'éditeur (délai d'approvisionnement : 14 jours).
Prix indicatif 344,85 €
Ajouter au panierThème de Retinal pharmacotherapeutics :
Mots-clés :
© 2024 LAVOISIER S.A.S.